---
title: "VSTM: VS-7375 shows promising efficacy and safety in KRAS G12D-mutated cancers, advancing to Phase 2 trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290604087.md"
description: "VS-7375 demonstrated broad anti-tumor activity and a favorable safety profile in advanced KRAS G12D-mutated solid tumors, with promising efficacy in pancreatic, colorectal, and lung cancers. Multiple Phase 2 trials are underway, and a collaboration will explore combination strategies.Original document: Verastem, Inc. [VSTM] Press release — Jun. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-23T20:12:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290604087.md)
  - [en](https://longbridge.com/en/news/290604087.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290604087.md)
generator: "portal-rs"
---

# VSTM: VS-7375 shows promising efficacy and safety in KRAS G12D-mutated cancers, advancing to Phase 2 trials

VS-7375 demonstrated broad anti-tumor activity and a favorable safety profile in advanced KRAS G12D-mutated solid tumors, with promising efficacy in pancreatic, colorectal, and lung cancers. Multiple Phase 2 trials are underway, and a collaboration will explore combination strategies.

Original document: Verastem, Inc. \[VSTM\] Press release — Jun. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md)

## Related News & Research

- [Verastem sets Oct. 14 investor event to present new VS-7375 KRAS G12D trial data across solid tumors](https://longbridge.com/en/news/298310904.md)
- [Bank of New York Mellon Corp Makes New Investment in Verastem, Inc. $VSTM](https://longbridge.com/en/news/298796234.md)
- [The AI doomsday debate intensifies](https://longbridge.com/en/news/298831736.md)
- [Erasca to present updated Phase 1 AURORAS-1 monotherapy data for ERAS-0015 at ENA Symposium](https://longbridge.com/en/news/298590990.md)
- [FTH: Oral multi-node inhibition demonstrates strong early efficacy and tolerability in cancer trials](https://longbridge.com/en/news/298617683.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**